Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Tirzepatide Dual agonist : GLP-1 + GIP Central benchmark for dual incretin research Often discussed in relation to body-weight outcomes, glycaemic control and incretin signalling Single agonist : GLP-1 More selective and mechanistically narrower Common reference point for GLP-1 pathway research Triple agonist : GLP-1 + GIP + glucagon Broader receptor profile than Tirzepatide Often discussed in relation to weight loss, energy expenditure and next-generation multi-pathway metabolic modulation For researchers comparing incretin classes, Tirzepatide often functions as the middle reference point between single-pathway GLP-1 agonists and broader triple-agonist designs
If you plan to discontinue tirzepatide, consider a gradual dose reduction over 8-12 weeks
No fillers or additives This product contains NO milk, egg, fish, peanuts, shellfish, soybeans, nuts, wheat, yeast, gluten, or corn products
Orforglipron 36w data underpins 1520% weightloss bar vs VKTX
